Cytokinetics
Trade Cytokinetics 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About CYTK
Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility.
CYTK Key Statistics
Stock Snapshot
With a market cap of 9.29B, Cytokinetics(CYTK) trades at $74.67. The stock has a price-to-earnings ratio of -11.45.
During the trading session on 2026-05-07, Cytokinetics(CYTK) shares reached a daily high of $74.99 and a low of $72.18. At a current price of $74.67, the stock is +3.4% higher than the low and still -0.4% under the high.
Trading volume for Cytokinetics(CYTK) stock has reached 4.42M, versus its average volume of 3.97M.
Over the past 52 weeks, Cytokinetics(CYTK) stock has traded between a high of $80.20 and a low of $29.31.
Over the past 52 weeks, Cytokinetics(CYTK) stock has traded between a high of $80.20 and a low of $29.31.
CYTK News
The investors in Cytokinetics, Incorporated's ( ) will be rubbing their hands together with glee today, after the share price leapt 26% to US$74.84 in the week...
Stifel raised the firm’s price target on Cytokinetics (CYTK) to $108 from $98 and keeps a Buy rating on the shares. Unlock hedge fund-level data and powerful i...
Maxwell Skor, an analyst from Morgan Stanley, maintained the Buy rating on Cytokinetics. The associated price target was raised to $103.00. Unlock hedge fund-l...
Analyst ratings
86%
of 22 ratingsMore CYTK News
Advertisement Why Cytokinetics Stock Is Back on Investors’ Radar Cytokinetics (CYTK) has climbed recently, with the stock up 16.7% over the past day and 27% o...
Cytokinetics ((CYTK)) has held its Q1 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks Unlock hedge fund-level data and powerf...
AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX AD...
Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...
Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Cytokinetics and keeping the price target at $136.00. Unlock hedge fund-level data and...
Cytokinetics (CYTK) stock rocketed higher on Tuesday after the late-stage biopharmaceutical company announced results from its ACACIA-HCM Phase 3 clinical trial...
Cytokinetics (CYTK) announced topline results from ACACIA-HCM, the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic non-obstructive hype...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.